A Meta-Analysis of the Accuracy of a Neuroendocrine Tumor mRNA Genomic Biomarker (NETest) in Blood
Introduction: The lack of an accurate blood biomarker in neuroendocrine tumor (NET) disease impedes effective management.
Aim(s): Review published data of a blood mRNA-based NET biomarker, the NETest.
Materials and methods: A systematic review using PRISMA guidelines. Ten original scientific papers, were identified. These were assessed by qualitative and then meta-analysis. Data were pooled and median (95% confidence interval [CI]) diagnostic odds ratio (DOR), positive likelihood ratio (+LR) and negative likelihood ratio (–LR) calculated. For the meta-analysis, a generic inverse variance method was undertaken using the accuracy and area under the curve (AUC) data.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Oberg K
To read the full abstract, please log into your ENETS Member account.